Ruxolitinib Shows Stronger Response in Primary Than Secondary HLH, Meta-Analysis Finds
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine